Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: Correlation with autopsy and M-mode echocardiography

doi:10.1016/S0894-7317(96)90019-X

Journal of the American Society of Echocardiography

Volume 9, Issue 2, March–April 1996, Pages 119-128

https://doi.org/10.1016/S0894-7317(96)90019-X Get rights and content

Abstract

The American Society of Echocardiography (ASE) has recommended diastolic area length and truncated ellipsoid methods for estimating left ventricular (LV) mass by two-dimensional (2D) echocardiography. The major goals of this retrospective study were to (1) assess the correlation between ASE-recommended 2D and M-mode echo-derived measurements of LV mass, (2) compare the two ASE-recommended 2D echocardiography methods, and (3) compare the echo-derived LV mass with anatomic LV mass. The study included 2D echocardiograms obtained within 30 days of death from 34 patients who subsequently underwent autopsy and 2D echocardiograms of 56 normal subjects. The formula used for measurement of M-mode echoderived LV mass was LV mass = 0.8 (ASE-cube LV mass) + 0.6 gm. For 2D echo-derived LV mass, the ASE-recommended area length and truncated ellipsoid methods in systole and diastole were used, with and without incorporating the papillary muscles into the myocardial shell. LV mass derived by M-mode echocardiography was comparable to that derived by 2D methods, and it is reasonable to use this technique for normally shaped ventricles. When the papillary muscles were included into the myocardial shell, diastolic 2D methods overestimated autopsy LV mass. Both diastolic area length and truncated ellipsoid methods were comparable to autopsy LV mass. When the papillary muscles were excluded, the systolic area length method showed the best agreement with autopsy LV mass.

References (28)

JN Woythaler et al.
Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: comparison with postmortem mass measurements
J Am Coll Cardiol
(1983)
JS Gottdiener et al.
Should echocardiography be performed to assess effects of antihypertensive therapy?
Test-retest reliability of echocardiography for measurement of left ventricular mass and function
J Am Coll Cardiol
(1995)
DL King et al.
Ultrasound beam orientation during standard two-dimensional imaging: assessment by three-dimensional echocardiography
J Am Soc Echocardiogr
(1992)
DL King et al.
Improved reproducibility of left atrial and left ventricular measurements by guided three-dimensional echocardiography
J Am Coll Cardiol
(1992)
EE Salcedo et al.
Left ventricular mass and wall thickness in hypertension: comparison of M mode and two dimensional echocardiography in two experimental models
Am J Cardiol
(1979)
RB Devereux et al.
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings
Am J Cardiol
(1986)
C Shub et al.
Determination of left ventricular mass by echocardiography in a normal population: effect of age and sex in addition to body size
BF Byrd et al.
Left ventricular mass and volume/mass ratio determined by two-dimensional echocardiography in normal adults
J Am Coll Cardiol
(1985)
D Levy et al.
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
N Engl J Med
(1990)
MJ Koren et al.
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
Ann Intern Med
(1991)

JK Ghali et al.

The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease

Ann Intern Med

(1992)

M Bikkina et al.

Left ventricular mass and risk of stroke in an elderly cohort

The Framingham Heart Study

JAMA

(1994)

RB Devereux et al.

Echocardiographic determination of left ventricular mass in man

Anatomic validation of the method

Circulation

(1977)

N Reichek et al.

Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings

Circulation

(1981)

Cited by (143)

Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer
2023, Journal of the American College of Cardiology
Body wasting in patients with cancer can affect the heart.
The frequency, extent, and clinical and prognostic importance of cardiac wasting in cancer patients is unknown.
This study prospectively enrolled 300 patients with mostly advanced, active cancer but without significant cardiovascular disease or infection. These patients were compared with 60 healthy control subjects and 60 patients with chronic heart failure (ejection fraction <40%) of similar age and sex distribution.
Cancer patients presented with lower left ventricular (LV) mass than healthy control subjects or heart failure patients (assessed by transthoracic echocardiography: 177 ± 47 g vs 203 ± 64 g vs 300 ± 71 g, respectively; P < 0.001). LV mass was lowest in cancer patients with cachexia (153 ± 42 g; P < 0.001). Importantly, the presence of low LV mass was independent of previous cardiotoxic anticancer therapy. In 90 cancer patients with a second echocardiogram after 122 ± 71 days, LV mass had declined by 9.3% ± 1.4% (P < 0.001). In cancer patients with cardiac wasting during follow-up, stroke volume decreased (P < 0.001) and resting heart rate increased over time (P = 0.001). During follow-up of on average 16 months, 149 patients died (1-year all-cause mortality 43%; 95% CI: 37%-49%). LV mass and LV mass adjusted for height squared were independent prognostic markers (both P < 0.05). Adjustment of LV mass for body surface area masked the observed survival impact. LV mass below the prognostically relevant cutpoints in cancer was associated with reduced overall functional status and lower physical performance.
Low LV mass is associated with poor functional status and increased all-cause mortality in cancer. These findings provide clinical evidence of cardiac wasting–associated cardiomyopathy in cancer.
Elevated heart rate as sympathetic biomarker in human obesity
2022, Nutrition, Metabolism and Cardiovascular Diseases
The present study was aimed at determining whether and to what extent a specific heart rate (HR) cutoff value allows to identify in obeses a more pronounced level of adrenergic overdrive.
In 86 obese subjects aged 44.7 ± 0.9 (mean ± SEM) years and in 45 heathy lean controls of similar age we evaluated muscle sympathetic nerve traffic (MSNA, microneurography) and venous plasma norepinephrine (NE, HPLC assay), subdividing the subjects in 3 different groups according to their resting clinic and 24-h HR values (<70, 70–79 and 80–89 beats/minute). MSNA and plasma NE values detected in the three obese groups were almost superimposable each other, no significant difference between groups being observed. A similar behavior was observed when HR values were assessed during the 24-h Holter monitoring. In the group as a whole no significant relationship was detected between MSNA, plasma NE and clinic HR, this being the case also when 24-h HR replaced clinic HR in the correlation analysis. In contrast lean controls displayed a progressive significant increase in MSNA values form the group with clinic (and 24 Holter) values below 70 beats/minute to the ones with HR values between 70 and 79 and above 80 beats/minute.
In the obese state measurement of resting HR may allow to provide some general information on the functional status of the adrenergic cardiovascular drive. When the information required, however, are more subtle the sensitivity of the approach appears to be reduced and HR cannot be regarded as a faithful sympathetic biomarker.
Left Ventricular Mass and Thickness: Why Does It Matter?
2019, Heart Failure Clinics
LV Mass Independently Predicts Mortality and Need for Future Revascularization in Patients Undergoing Diagnostic Coronary Angiography
2018, JACC: Cardiovascular Imaging
The goal of this study was to assess associations between left ventricular (LV) mass, all-cause mortality, and need for revascularization in patients undergoing coronary angiography.
LV hypertrophy is associated with adverse cardiovascular outcomes in healthy subjects. However, its influence in those with known or suspected coronary artery disease is poorly understood.
A total of 3,754 patients (mean age 59.3 ± 13.1 years) undergoing invasive coronary angiography and cardiac magnetic resonance (CMR) (mean interval 1.0 ± 1.5 months) were studied. LV mass and volumes were determined from cine images and indexed to body surface area. Analyses were adjusted for CMR variables, medical comorbidities, and severity of coronary artery disease (Duke Jeopardy Score) and were stratified to LV function.
At a median of 44.9 months, 315 patients (8.4%) died and 168 patients (4.5%) underwent revascularization. Multivariable analysis showed that each 10 g/m² increase in LV mass index was associated with a 6% greater risk of mortality (hazard ratio: 1.06; 95% confidence interval [CI]: 1.01 to 1.11; p = 0.02) and a 10% greater need for revascularization (hazard ratio: 1.10; 95% CI: 1.04 to 1.17; p < 0.01). According to pre-defined thresholds, moderate to severe hypertrophy was associated with a 1.7-fold risk of mortality (95% CI: 1.2 to 2.3) and 1.8-fold need for revascularization (95% CI: 1.18 to 2.67). These findings were predominantly observed in those with a left ventricular ejection fraction >35% with respective hazard ratios of 2.93 (95% CI: 1.92 to 4.47) and 2.20 (95% CI: 1.21 to 3.98).
LV mass index is an independent predictor of all-cause mortality and need for revascularization. This finding establishes relevance for LV mass measurements in clinical decision-making surrounding both the need and timing of revascularization in this population.
Influence of stentless versus stented valves on ventricular remodeling assessed at 6 months by magnetic resonance imaging and long-term follow-up
2017, Journal of Cardiology
Citation Excerpt :
Aortic regurgitation was graded as absent, trivial, mild, moderate, or severe based on standard clinical criteria, including assessment of jet width, circumference, and eccentricity. LVM index was calculated using the modified American Society of Echocardiography cube method [18]. A patient prosthesis mismatch was defined according to the following criteria [19]: as “none” if the indexed EOA was >0.85 cm2/m2, as “moderate” if the indexed EOA was 0.65–0.85 cm2/m2, and as “severe” for values <0.65 cm2/m2.
To compare the effect of stented versus stentless bioprostheses on left ventricular remodeling and assess their impact on long-term survival.
From January 2002 to December 2009, 62 severe aortic stenosis patients without coronary artery disease were randomized for bioprosthetic aortic valve replacement. After randomization, a cross-over was possible based on intraoperative data. Ventricular remodeling was studied by cardiovascular magnetic resonance imaging six months after surgery. Long-term survival was assessed by telephone survey.
Thirty-five patients received a porcine Mosaïc^® Medtronic bioprosthesis (Stented Group; Medtronic, Minneapolis, MN, USA) inserted using the usual supra-annular technique and 27 received a porcine Freestyle^® Medtronic bioprosthesis (Stentless Group) inserted in the subcoronary position. Mean age was 75 ± 3 and 73 ± 4 years in the stentless and stented group, respectively. Nine patients who should have been implanted with a stentless bioprosthesis received a stented bioprosthesis for anatomical reasons. At 6 months, the left ventricular mass (LVM) decreased significantly in both groups (Stentless Group: 214.6 ± 56.1 g and 156.3 ± 23 g and Stented Group: 237 ± 75.7 g and 181 ± 53.3 g, respectively after surgery and at 6 months), this decrease was significantly greater in the stentless group (p = 0.026). Reserve and coronary flow were increased in both groups at 6 months. Mean follow-up duration was 6.6 ± 3.0 years and 7.2 ± 4.0 years in the stentless and stented group, respectively. The 5-year actuarial survival was 87.5 ± 11.7% and 82.5 ± 17.1% for the stentless and stented group, respectively (p = 0.81).
Porcine stentless prosthesis results in a better LVM regression than a stented valve at 6 months without changing the long-term survival.
Prognostic Implications of Left Ventricular Hypertrophy
2018, Progress in Cardiovascular Diseases
Left ventricular hypertrophy (LVH) was one of the earliest studied echocardiographic characteristics of the left ventricle. As the myriad of measurable metrics has multiplied over recent years, this reliable and relevant variable can often be overlooked. In this paper, we discuss appropriate techniques for accurate analysis, underlying pathophysiology, and the contributions from various risk factors. The prognostic implications of LVH on stroke, serious arrhythmias, and sudden cardiac death are reviewed. Finally, we examine the effect of therapy to reduce LVH and the resultant clinical outcomes.

View all citing articles on Scopus

View full text

Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: Correlation with autopsy and M-mode echocardiography

Abstract

J Am Coll Cardiol

J Am Coll Cardiol

J Am Soc Echocardiogr

J Am Coll Cardiol

Am J Cardiol

Am J Cardiol

J Am Coll Cardiol

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

N Engl J Med

Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension

Ann Intern Med

The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease

Ann Intern Med

Left ventricular mass and risk of stroke in an elderly cohort

The Framingham Heart Study

JAMA

Echocardiographic determination of left ventricular mass in man

Anatomic validation of the method

Circulation

Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings

Circulation